Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase NA 1Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28Myelodysplastic Syndromes 10Leukemia, Myeloid, Acute 7Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Polycythemia Vera 3Myeloproliferative Disorders 3Bronchiolitis Obliterans Syndrome 3Blast Crisis 3Neoplasms, Plasma Cell 2Neoplasms 2Mastocytosis, Systemic 2Lymphoma 2Lymphohistiocytosis, Hemophagocytic 2Leukemia, Myeloid, Chronic-Phase 2Hematologic Diseases 2Graft vs Host Disease 2Anemia, Aplastic 2Waldenstrom Macroglobulinemia 1Vitamin D Deficiency 1Thrombocytopenia 1Thalassemia 1Recurrence 1Purpura, Thrombocytopenic, Idiopathic 1Primary Myelofibrosis 1Piebaldism 1Philadelphia Chromosome 1Patient Compliance 1Pathologic Processes 1Oligodendroglioma 1

Interventions

ruxolitinib 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Thalassemia × Myeloid × Clear all
NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Novartis

Phase 4 Active not recruiting
279 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡